Robert “Robin” Bellas
Robin has directed the exits of over 20 portfolio companies with a combined value of $10 billion. He started Morgenthaler’s Life Science team in 2001 and the Firm’s incubation strategy with The Foundry and ForSight Labs. More recently, he has invested in and served as a director of Ardian, Miramar, ForSight Vision2, ForSight Vision4, Nexis Vision and Transcend.
In January 2011 Medtronic purchased Ardian for $800 million plus uncapped annual revenue growth milestones over five years. Robin led Morgenthaler’s early financings in Ardian and served as a director of the company.
Robin operated in two Silicon Valley startups prior to Morgenthaler. He is a past director of the Western Association of Venture Capitalists (WAVC) and of the Stanford Business School Trust. Before Stanford, he served on nuclear submarines. He has a BS in Engineering from the US Naval Academy and an MBA from the Stanford Graduate School of Business.